ArticleFrontiers in oncology2026
Prognostic value of initial recurrence pattern for post-recurrence survival in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative recurrence remains a major cause of treatment failure and death in patients with locally advanced rectal cancer (LARC), despite advances in neoadjuvant chemoradiotherapy (NCRT) and radical surgery. This study evaluated the prognostic value of initial recurrence patterns on post-recurrence survival (PRS) and examined clinicopathological factors associated with recurrence-free survival (RFS). Methods: This retrospective study included 437 patients with LARC who underwent NCRT followed by surgery. In the cohort without preoperative metastasis, RFS was analyzed using the Kaplan-Meier method and Cox proportional hazards regression models. Among patients who developed postoperative recurrence, initial recurrence patterns were categorized as isolated lung metastasis, isolated liver metastasis, or complex recurrence based on the first site of recurrence. PRS was analyzed with the Kaplan-Meier method, and prognostic factors were identified through Cox proportional hazards regression models. A 2-year landmark analysis was conducted to assess subsequent overall survival (OS) according to recurrence status within 2 years after surgery. Results: Among the 437 patients, 347 remained recurrence-free, 28 had preoperative metastasis, and 62 developed postoperative recurrence. In the curative-intent cohort, multivariable Cox regression analysis indicated that pathological tumor deposit (pTD) positivity (HR, 2.37; P = 0.006) and ypTNM stage II-III (HR, 1.923; P = 0.012) were independently associated with shorter RFS. Multivariable Cox regression analysis showed that the initial recurrence pattern was independently associated with PRS. Compared with isolated lung metastasis, complex recurrence was consistently associated with poorer PRS, whereas isolated liver metastasis showed an intermediate prognosis. Kaplan-Meier analysis further revealed notable differences in PRS among recurrence patterns, with isolated lung metastasis having the most favorable outcome and complex recurrence the poorest prognosis. Additionally, recurrence within 2 years after surgery was linked to significantly lower subsequent OS in the 2-year landmark analysis. Conclusions: The initial postoperative recurrence pattern was independently associated with PRS in patients with LARC following NCRT and surgery. Isolated lung metastasis was associated with relatively better outcomes, while complex recurrence indicated a poorer prognosis. In the curative-intent group, higher ypTNM stage and pTD positivity were independently associated with worse RFS. These findings may help improve postoperative risk stratification and support personalized surveillance and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.